StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $16.70 | $17.20 | +2.99% | 0.9M |
| 05-19 | $17.28 | $17.82 | +3.12% | 0.7M |
| 05-20 | $17.81 | $18.08 | +1.52% | 0.9M |
| 05-21 | $18.07 | $18.16 | +0.50% | 1.7M |
| 05-22 | $18.25 | $18.31 | +0.33% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $171.17M | $719.89M | $536.78M | $344.94M |
Operating Income | $13.63M | $140.40M | $104.80M | $79.48M |
Net Income | $6.42M | $98.09M | $73.67M | $31.03M |
EPS (Diluted) | $0.14 | $2.03 | $1.52 | $1.15 |
Total Assets | $1.65B | $1.63B | $1.67B | $1.62B |
Total Liabilities | $874.77M | $840.49M | $889.48M | $857.85M |
Cash & Equivalents | $170.94M | $170.18M | $216.26M | $187.69M |
Free Cash Flow OCF − CapEx | $38.33M | $121.23M | $96.64M | $49.41M |
Shares Outstanding | 44.64M | 45.65M | 46.35M | 46.49M |